Abstract
The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.
Keywords: chemotherapy, death domain, death effector domain, DISC, FADD, c-FLIP,, scaffold, TRAIL, TRAIL-R4, APO2-L
Recent Patents on Anti-Cancer Drug Discovery
Title: Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Volume: 6 Issue: 3
Author(s): Sarah Shirley, Alexandre Morizot and Olivier Micheau
Affiliation:
Keywords: chemotherapy, death domain, death effector domain, DISC, FADD, c-FLIP,, scaffold, TRAIL, TRAIL-R4, APO2-L
Abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.
Export Options
About this article
Cite this article as:
Shirley Sarah, Morizot Alexandre and Micheau Olivier, Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957757
DOI https://dx.doi.org/10.2174/157489211796957757 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds From Protein to Peptides: a Spectrum of Non-Hydrolytic Functions of Acetylcholinesterase
Protein & Peptide Letters Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics Challenges and Opportunities in Molecular Imaging
Current Medical Imaging Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Translational Multimodality Neuroimaging
Current Drug Targets Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation